Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Weekly Wrap 16 September

Grady Wulff
September 16, 2022

Morning Bell 16 September

Sophia Mavridis
September 16, 2022

Morning Bell 15 September

Sophia Mavridis
September 15, 2022

Closing Bell 14 September

Grady Wulff
September 14, 2022

Morning Bell 14 September

Grady Wulff
September 14, 2022

Closing Bell 13 September

Grady Wulff
September 13, 2022

Morning Bell 13 September

Paulina Peters
September 13, 2022

Closing Bell 12 September

Grady Wulff
September 12, 2022

Morning Bell 12 September

Grady Wulff
September 12, 2022

Weekly Wrap 9 September

Grady Wulff
September 9, 2022

Morning Bell 9 September

Sophia Mavridis
September 9, 2022

Closing Bell 8 September

Grady Wulff
September 8, 2022